Here are three takeaways:
1. The patents are for its lead product CybroCell, an off-the-shelf allogenic human dermal fibroblast product to treat degenerative disc disease.
2. Throughout several clinical trials, CybroCell demonstrated improved pain relief and increased back mobility in patients treated with the fibroblast.
3. SpinalCyte has 35 U.S. and foreign patents issued and 41 patents pending.
More articles on biologics:
3 things to know about Lattice Biologics’ CEO
Cellect receives patent approval for Apograft technology: 3 notes
OsteoRemedies unveils 1st FDA-cleared dual-antibiotic spacer & bone cement: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.